Empire Monitor

Not Elon Musk. Not financial Advice. DYODD. Some posts contain partner content.

[Empire Monitor @Empire_Monitor]

Collecting robot training data is dirty, unglamorous work. Some AI labs are already paying XDOF to do it.

https://t.co/6PW3wu6UHD

[Empire Monitor @Empire_Monitor]

$PTN: What does a $6.5 billion company's clinical win mean for a $21 million competitor playing the same field?

Rhythm Pharmaceuticals has spent years establishing MC4R agonism as a viable treatment strategy in rare obesity. This month's ENDO 2026 data in Prader-Willi syndrome, showing 3.11% BMI reduction in adults and 3.00% in pediatric patients with 17 of 18 patients staying on drug, is the latest chapter in that case. When category leaders keep posting data, they also keep validating the biology. That matters for every company working in the same pathway.

Palatin is designing the second generation of MC4R therapy. The core differentiation is selectivity at MC4R versus MC1R. Less MC1R activity means less hyperpigmentation. In a rare disease context where patients are often young and on therapy indefinitely, tolerability shapes clinical practice in ways that efficacy benchmarks alone do not capture.

https://t.co/0CUvMkWSMy

Next catalyst: once-weekly injectable MC4R peptide IND submission targeted for Q4 2026, the regulatory filing that opens Phase 1 testing and the first clinical test of PTN's selectivity-first design approach.

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Palatin Technologies, Inc. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

Kevin Warsh steps into his first Fed decision today - and the backdrop couldn't be more complex.

Rates on hold is a near-certainty, but the real story is the dot plot. May CPI hit 4.2% YoY, PCE running at 3.8%, and 17 of 32 former Fed officials now think a hike may be needed before year-end. Markets started 2026 pricing two cuts. Now they're pricing zero.

The Iran peace deal just gave Warsh some breathing room on oil prices - but inflation was already broadening before the war. Watch how he frames that distinction today.

https://t.co/woOIcwioZC

[Empire Monitor @Empire_Monitor]

$EMAT is not a mining story. That is the distinction most investors overlook when they scan the rare earth trade on NASDAQ. While peer names are upstream miners still projecting future magnet output, EMAT's Korean subsidiaries have produced and shipped finished sintered magnets to Ford, Hyundai, and Samsung for nearly 18 years. Commercial production is not the plan. It is the baseline.

China controls an estimated 90% of global refining and high-performance magnet manufacturing. When Beijing expanded export controls in April 2025, Ford's CEO described his company's magnet supply as "day to day" and "hand to mouth." A Chicago plant halted. Every U.S. defense prime faces the same exposure. The market for a credible, non-China sintered magnet supplier is not theoretical. It has a statutory deadline attached to it.

EMAT has stacked: a $100 million commitment from Yorkville Advisors (May 11, 2026), binding purchase orders for 13 ULVAC furnaces targeting 10,000 metric tons of annual capacity including 6,000 metric tons of high-performance sintered grades (May 14, 2026), and a defense-credentialed board including Christopher C. Miller, Acting U.S. Secretary of Defense under Trump. Following these moves, in June 2026, the company completed customer quality certification across six sintered NdFeB magnet grades with two leading global Tier-1 electronics OEMs.

Next catalyst: the DFARS defense-prime qualification process. Korean-certified magnet grades now need to clear U.S. defense contractor acceptance procedures, and announcements of signed defense offtake agreements will be the commercial inflection point for EMAT's defense revenue story.

https://t.co/z0ekplhxIH

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Evolution Metals & Technologies Corp. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

Who do you hire to take a proven-but-small defense drone company to the next level after a Nasdaq uplisting? A man who spent a decade-plus at Rafael Advanced Defense Systems, the maker of Iron Dome and David's Sling, and then became CEO of SpearUAV, the VIPER loitering munition startup that sold to UVision in 2025.

https://t.co/i37b5UE7Jn

Yiftach Kleinman is stepping in as CEO of Duke Robotics, effective no later than September 8, 2026. He served as a Colonel in the IDF active reserve. Before SpearUAV, his time at Rafael included running M&A across a portfolio of defense subsidiaries and leading international business development campaigns that generated billions in contracts with the US, Europe, and Asia Pacific.

$DUKR just listed on Nasdaq in May 2026 with a $9.2 million raise. Its Bird of Prey weapons drone is already in active IDF operational use, co-marketed by Elbit. Its IC Drone service is deep into its largest-ever season with Israel Electric Corporation. Yossef Balucka moves to President to lead commercial platform growth, while Kleinman takes the defense mandate.

The parallel to SpearUAV is the one worth watching. Kleinman took that company's validated loitering munition technology from production to international contracts to a strategic exit. The question for Duke Robotics is whether the same arc applies to the Bird of Prey.

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Duke Robotics Corp. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

What does a 97% production yield mean for a quantum hardware company that makes no qubits, only the layer that makes qubits possible? For $QTEX, it means one of the largest U.S.-based interconnect manufacturers just moved its AME platform off the development bench and onto the production floor.

The manufacturer ran hundreds of technical and process evaluations covering reliability, vibration, environmental exposure, humidity, and assembly integration. QTREX's AME system cleared 97% yield. That is a production-ready outcome.

Quantum hardware scales when the interconnect layer scales. IBM, IonQ, Rigetti, and D-Wave all build systems that must eventually route signals out of a dilution refrigerator operating near absolute zero. The wiring to do that, at high qubit counts, is a problem that hand-assembled cables cannot solve. QTREX prints a monolithic solution. Today that printed solution runs in production.

The company is advancing discussions for additional AME systems and manufacturing expansion. Watch whether those discussions surface as named agreements at https://t.co/0BmBTqz8ke World 2026 in Boston, June 25-26.

https://t.co/l7bgn4IWYt

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. QTREX Quantum Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

What does it actually take to turn a peptide that has only ever been injected into a once-daily oral tablet? Entera Bio's EB618 was tested in non-human primates at more than ten times the anticipated clinical dose range, showed dose-proportional pharmacokinetics across three tablet strengths, and produced a dose-proportional glucose effect. No safety concerns at any dose level.

EB618 is a dual GLP-1/glucagon receptor agonist built on oxyntomodulin, a naturally occurring peptide hormone that acts on both receptors simultaneously. That dual mechanism gives it appetite suppression, weight loss effects, glucose regulation, and documented cardioprotective and anti-fibrotic properties that a pure GLP-1 agonist does not carry.

https://t.co/JekECrCvE9

$ENTX's N-Tab platform is now generating converging evidence across four oral peptide programs: EB613 for osteoporosis, EB612 for hypoparathyroidism, EB618 for obesity, and an oral GLP-2 for short bowel syndrome, all developed in collaboration with OPKO Health. The February 2026 OPKO partnership expansion onto 50/50 terms for EB612, the April 2026 BVF direct investment ($10 million in initial proceeds, potential up to $24.5 million total), and now a three-program ENDO 2026 data showing have together compressed the platform risk profile considerably compared to twelve months ago.

Next catalyst: Phase 3 initiation for EB613 in late 2026, following FDA feedback on the streamlined protocol submitted in March 2026 targeting a 750-patient, 12-month endpoint study.

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Entera Bio Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

Sundar Pichai faces boos, walkout at Stanford graduation ceremony over Google’s Israel, ICE ties

https://t.co/LjIVFY6Ebw

[Empire Monitor @Empire_Monitor]

Nvidia raised $25B in bonds - its first debt sale since 2021 - and attracted $85B in investor demand.

The interesting part: the primary reason wasn't to fund AI capex. It was to establish a liquid benchmark for its cost of credit.

When the world's most profitable chip company borrows not out of need but to price itself in the debt market, that's a signal about where the AI capital cycle is heading. $NVDA

https://t.co/i0WZz7RfJc

[Empire Monitor @Empire_Monitor]

This week, the shape of the rare earth supply question shifted. It is no longer about whether a credible non-China alternative exists. Today's news from $EMAT is about whether the supply chain is certified, scaled, and ready to meet the January 2027 defense procurement deadline.

The answer, as of June 11: certified across six sintered NdFeB grades, including the heavy rare earth super-high-temperature compositions used in defense systems and EV traction motors. The Korean operating subsidiaries carry an 18-plus year production history, a team of 42 engineers and 11 PhDs, and a binding purchase order placed May 14 for 13 ULVAC machines arriving November 2026, targeting annual capacity of approximately 10,000 metric tons.

China's April 2025 and October 2025 export controls on heavy rare earths are active. The U.S.-Korea Critical Minerals Framework, finalized April 17, 2026, reinforces the strategic value of the Korean platform. The Trump administration's January 2026 Section 232 Proclamation named rare earth permanent magnets as vital to national security. The industrial policy environment and the OEM certifications are now aligned.

Next catalyst: January 1, 2027, when DFARS 252.225-7052 takes effect. U.S. defense contractors will formally be unable to source Chinese-origin rare earth magnets in covered systems. Six certified grades are in commercial production outside China today.

https://t.co/gFcb5G4sdJ

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Evolution Metals & Technologies Corp. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

$95 billion. That is the projected annual US cost of osteoporotic fractures by 2040. It is also the backdrop against which Entera Bio has been quietly executing a precise clinical build, and today’s ENDO 2026 Phase 1 data is the bridge that completes the pre-Phase 3 evidence package for $ENTX.

https://t.co/yUZJNnc9Ek

The Phase 1 bridging study (NCT05965167, 15 participants) confirmed that Entera’s single-tablet EB613 formulation matches the pharmacokinetics of both the multi-tablet format used in the successful 161-patient Phase 2 study and subcutaneous Forteo® by Eli Lilly. AUC comparable. PD response comparable. Safety clean. Patient preference: all 15 participants chose daily oral EB613 over the daily injection, with 14 of 15 preferring the single tablet over the multi-tablet format.

On the financial side, Entera reported $20.4 million in available funds as of May 8, 2026, covering operations through Q1 2027. That figure includes $7.8 million in restricted cash earmarked for OPKO collaboration programs (EB612, EB618). The April 2026 BVF Partners investment of $10 million funded Phase 3 preparation, with five-year warrants carrying the potential for up to $14.5 million in additional proceeds.

Watch the $20.4 million cash position against Phase 3 site activation costs. The BVF warrants become exercisable six months after the April 2026 closing, and their exercise would bring up to $14.5 million in additional proceeds to extend the runway through the Phase 3 enrollment ramp.

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Entera Bio Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

After tracking ten consecutive Quantum Cyber press releases, one pattern has been constant: every technology layer announced is described as part of the same System-of-Systems defense platform, with the quantum antenna consistently named at the top of the stack. With more than $15 million in cash and a debt-free balance sheet, $QUCY has now executed the signed agreement that actually puts it there.

The June 11, 2026 IP License Agreement with Project LightShift, Inc. grants Quantum Cyber exclusive worldwide rights to develop, manufacture, and commercialize the patent-protected quantum photonic array technology for defense UAV applications. The technology uses nano multi-spectrum lenses and controllable diode lasers communicating via multi-frequency photonic signals in a nearest-neighbor configuration, verified through Near Field Quantum electrodynamics. Manufacturing methods combine self-assembly and epitaxial growth techniques.

The agreement structure includes a vesting schedule protecting QUCY's equity and contractual protections that allow the company to retain these rights permanently even if Project LightShift fails to meet its obligations. Quantum Cyber will file a Form 8-K with the SEC disclosing the full transaction details.

Prototype testing and real-world deployment are the next milestones explicitly stated in this press release. That announcement is the next concrete event in this story.

https://t.co/jnqqXcoCgM

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Quantum Cyber N.V. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

As Anthropic suspends access to new models, India debates its AI future

The announcement came late Friday, when Anthropic said it had received the U.S. government directive requiring it to suspend access to its recently launched Fable 5 and Mythos 5 models for all foreign nationals, including its own foreign national employees.

https://t.co/cBL5ICjvZR

[Empire Monitor @Empire_Monitor]

Markets cheered the US-Iran deal - MSCI Asia Pacific up 3.2%, oil tumbling, Treasury yields falling.

But strategists at KCM Trade, Pepperstone, and Stifel Nicolaus are calling it a short-term trade, not a sustained rally. The inflation damage from months of Hormuz disruption doesn't vanish with a ceasefire. Shipowners, insurers, and refiners still need to rebuild confidence - analysts say that takes months, not days.

Peace deals open doors. They don't instantly fix supply chains.

https://t.co/jJzr0E7rg1

[Empire Monitor @Empire_Monitor]

Most new treatments for recurrent glioblastoma eventually hit the same wall. Promising early signals, disappointing outcomes at scale, then silence. That cycle has repeated often enough that the oncology field approaches new data in this indication with earned skepticism.

Which makes the FDA's decision this week worth reading carefully. Regulators reviewed a pre-specified interim safety report on the first three patients treated in Alpha Tau Medical Ltd.'s REGAIN trial at The Ohio State University Comprehensive Cancer Center. Those patients, treated between December 2025 and March 2026, showed 100% local disease control and a 67% complete response rate by RANO criteria. One grade 3 serious adverse event was observed and resolved. No unanticipated adverse events. No local or distant recurrence. No residual symptoms from the procedure. The FDA cleared $DRTS to enroll the final seven patients and authorized two additional U.S. academic sites.

https://t.co/yghsOkNLsW

This is a ten-patient feasibility and safety study. Full-cohort data are not yet in hand. But the regulatory track record here is real: Breakthrough Device Designation in October 2021, acceptance into the FDA's Total Product Life Cycle Advisory Program in October 2024, and now clearance to complete enrollment on the strength of a clean early safety read. Approximately 14,000 Americans are newly diagnosed with glioblastoma each year, and median survival after recurrence is measured in months. Alpha Tau Medical Ltd. is operating simultaneously across pancreatic cancer, skin cancer, and prostate cancer programs, backed by a $20 million Tolmar equity investment, up to $161.5 million in partnership milestones, and $80.2 million in liquidity. The REGAIN full-cohort data will be the next meaningful inflection point.

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Alpha Tau Medical Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

SpaceX's $75B IPO is historic - but the real story is what happens next.

$SPCX closed +19% on debut, valuing a company losing $4.9B/year at $2.1T. Morningstar pegs fair value at $63/share. The "Dean of Valuation" called its $28.5T addressable market a "hallucination."

Yet pension funds may have no choice but to buy in - Nasdaq's new 15-day index rule means passive investors get exposure whether they want it or not.

https://t.co/lryjtR6R3d

[Empire Monitor @Empire_Monitor]

Three facts about Quantum Cyber's balance sheet as of June 12, 2026.

Over $15 million in gross proceeds received from warrant exercises in May 2026. All outstanding debt obligations fully satisfied and extinguished. Zero exercisable warrants remaining on the cap table. The result: Quantum Cyber N.V. (Nasdaq: $QUCY) has terminated its at-the-market issuance agreement with Maxim Group LLC, effective June 7, 2026. The ATM was originally dated October 1, 2025, was amended once on May 4, 2026, and sat completely unused for the two months before its termination. Management's stated position is that the existing cash position provides sufficient runway to fund all disclosed strategic objectives without further equity issuance.

Those objectives are concrete and active. Subsidiary Quantum Drones Corporation holds an active LOI to acquire a 43,000-square-foot manufacturing facility in Bridgeport, Connecticut at a proposed purchase price of $3.2 million, intended to anchor in-house autonomous drone production. An Advanced Filament Manufacturing Division is being established to produce patented EMP-hardened composite filament alongside standard PETG for an 80-unit 3D printer drone production farm, with the company asserting no domestic competitor offers comparable broadband EMP/EMI shielding in an FDM-compatible commercial format. Patent prosecution continues across solid rocket motor propulsion, quantum swarm navigation for autonomous ground vehicle fleets, and counter-UAS architectures. The company's System-of-Systems platform covers drone warfare, counter-UAS, naval mine countermeasures, EMP shielding, and anti-drone ammunition, targeting a DoD autonomous warfare procurement environment the company has cited at approximately $55 billion in FY2027 budget allocations.

https://t.co/AVxsgSF1jg

_
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Quantum Cyber N.V. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: https://t.co/e8Ttqq9LeX. Our content is not financial advice.

[Empire Monitor @Empire_Monitor]

The ECB just became the first G7 central bank to hike rates since the Iran war - raising to 2.25% as eurozone inflation hit 3.2% in May.

Meanwhile, the Fed is widely expected to hold next week. That's a striking divergence: Europe tightening to fight an energy-driven inflation shock while the U.S. stays on pause.

Watch how long this split can last before one side blinks.

https://t.co/3A1G7m7ztZ

[Empire Monitor @Empire_Monitor]

Markets are rallying on Iran peace hopes - but here's the uncomfortable truth for oil producers: Hormuz reopening could be OPEC's undoing.

With OPEC's global production share already at an all-time low of ~22%, revenue-starved members will race to maximize exports once the strait reopens. Rystad Energy sees a potential 5 million bpd surplus. The UAE already quit the group. Saudi Arabia's leverage is weakened.

Peace may finally arrive. OPEC's era of market control may not survive it.

https://t.co/U7sJ86gZyh

[Empire Monitor @Empire_Monitor]

These are the countries moving to ban social media for children

https://t.co/uZHHWpMCJs